U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
Portfolio Pulse from
Jaguar Health has initiated a U.S. Investigator-Initiated Trial (IIT) to evaluate its drug Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF). The drug has received Orphan Drug Designation from the FDA and EMA, and results are expected by Q2 2025.
December 06, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health has started a U.S. trial for Crofelemer, targeting SBS-IF. The drug has Orphan Drug Designation from the FDA and EMA, indicating potential market exclusivity and support. Results are expected by Q2 2025.
The initiation of the trial and the Orphan Drug Designation are positive indicators for Jaguar Health, potentially leading to market exclusivity and increased investor interest. The expected results in Q2 2025 could further impact the stock positively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100